New drug ABBV-319 takes aim at Hard-to-Treat blood cancers

NCT ID NCT05512390

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an investigational drug called ABBV-319 in about 154 adults with certain B-cell cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The study has two parts: first, finding a safe dose, then checking how well that dose controls the cancer. Participants receive the drug by IV every 21 days and are closely monitored for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-319 (an investigational drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with certain B-cell cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not shrink tumors or could cause serious side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma neoplasm relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B-CELL LYMPHOMA FOLLICULAR LYMPHOMA

Contacts and locations

Locations

Allina Health System /ID# 251782
RECRUITING

Minneapolis, Minnesota, 55407-1321, United States
Asan Medical Center /ID# 263220
RECRUITING

Seoul, Seoul Teugbyeolsi, 05505, South Korea
Baylor Sammons Cancer Center /ID# 247715
RECRUITING

Dallas, Texas, 75246, United States
Concord Repatriation General Hospital /ID# 249240
RECRUITING

Concord, New South Wales, 2139, Australia
Cross Cancer Institute /ID# 246717
COMPLETED

Edmonton, Alberta, T6G 1Z2, Canada
Hadassah Medical Center-Hebrew University /ID# 254885
RECRUITING

Jerusalem, 91120, Israel
Hospital Universitario Fundacion Jimenez Diaz /ID# 265198
RECRUITING

Madrid, 28040, Spain
Hospital Universitario Marques de Valdecilla /ID# 262826
RECRUITING

Santander, Cantabria, 39008, Spain
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 249246
RECRUITING

New York, New York, 10065-6007, United States
Novant Health Presbyterian Medical Center /ID# 246719
RECRUITING

Charlotte, North Carolina, 28204, United States
One Clinical Research Pty Ltd /ID# 248392
RECRUITING

Nedlands, Western Australia, 6009, Australia
Samsung Medical Center /ID# 263294
RECRUITING

Seoul, Seoul Teugbyeolsi, 06351, South Korea
Seoul National University Hospital /ID# 263945
RECRUITING

Seoul, Seoul Teugbyeolsi, 03080, South Korea
St Vincent's Hospital Melbourne /ID# 247624
RECRUITING

Fitzroy Melbourne, Victoria, 3065, Australia
Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232
COMPLETED

Miami, Florida, 33136, United States
The Chaim Sheba Medical Center /ID# 254884
COMPLETED

Ramat Gan, Tel Aviv, 5265601, Israel
University Health Network_Princess Margaret Cancer Centre /ID# 243936
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
University of Arizona Cancer Center - Tucson /ID# 247752
RECRUITING

Tucson, Arizona, 85724, United States
University of Nebraska Medical Center /ID# 246715
RECRUITING

Omaha, Nebraska, 68198, United States
University of Texas Health San Antonio MD Anderson Cancer Center /ID# 256234
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.